It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Body fat distribution is a major, heritable risk factor for cardiometabolic disease, independent of overall adiposity. Using exome-sequencing in 618,375 individuals (including 160,058 non-Europeans) from the UK, Sweden and Mexico, we identify 16 genes associated with fat distribution at exome-wide significance. We show 6-fold larger effect for fat-distribution associated rare coding variants compared with fine-mapped common alleles, enrichment for genes expressed in adipose tissue and causal genes for partial lipodystrophies, and evidence of sex-dimorphism. We describe an association with favorable fat distribution (p = 1.8 × 10−09), favorable metabolic profile and protection from type 2 diabetes (~28% lower odds; p = 0.004) for heterozygous protein-truncating mutations in INHBE, which encodes a circulating growth factor of the activin family, highly and specifically expressed in hepatocytes. Our results suggest that inhibin βE is a liver-expressed negative regulator of adipose storage whose blockade may be beneficial in fat distribution-associated metabolic disease.
Fat distribution is associated with cardiometabolic disease, although it has been less well studied than overall obesity. In a multiancestry exome-sequencing study, the authors identified predicted loss-of-function mutations in INHBE associated with favorable fat distribution and protection from type 2 diabetes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






















1 Regeneron Pharmaceuticals Inc, Regeneron Genetics Center, Tarrytown, USA (GRID:grid.418961.3) (ISNI:0000 0004 0472 2713)
2 Regeneron Pharmaceuticals Inc, Tarrytown, USA (GRID:grid.418961.3) (ISNI:0000 0004 0472 2713)
3 Geisinger Health System, Department of Molecular and Functional Genomics, Danville, USA (GRID:grid.280776.c) (ISNI:0000 0004 0394 1447)
4 Geisinger Health System, Geisinger Obesity Institute, Danville, USA (GRID:grid.280776.c) (ISNI:0000 0004 0394 1447)
5 Lund University, Department of Clinical Sciences Malmö, Malmö, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); University of Verona, Department of Medicine, Verona, Italy (GRID:grid.5611.3) (ISNI:0000 0004 1763 1124)
6 Lund University, Department of Clinical Sciences Malmö, Malmö, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
7 Unidad de Medicina Experimental de la Facultad de Medicina de la Universidad Nacional Autónoma de México, Mexico City, Mexico (GRID:grid.9486.3) (ISNI:0000 0001 2159 0001)
8 Unidad de Medicina Experimental de la Facultad de Medicina de la Universidad Nacional Autónoma de México, Mexico City, Mexico (GRID:grid.9486.3) (ISNI:0000 0001 2159 0001); Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Mexico (GRID:grid.419886.a) (ISNI:0000 0001 2203 4701)
9 University of Oxford, MRC Population Health Research Unit, Nuffield Department of Population Health, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Clinical Trial Service Unit & Epidemiological Studies Unit Nuffield Department of Population Health, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
10 University of Oxford, Clinical Trial Service Unit & Epidemiological Studies Unit Nuffield Department of Population Health, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
11 University of Pennsylvania, Department of Genetics, Perelman School of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
12 Regeneron Pharmaceuticals Inc, Regeneron Genetics Center, Tarrytown, USA (GRID:grid.418961.3) (ISNI:0000 0004 0472 2713); Regeneron Pharmaceuticals Inc, Tarrytown, USA (GRID:grid.418961.3) (ISNI:0000 0004 0472 2713)
13 Lund University, Department of Clinical Sciences Malmö, Malmö, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Skåne University Hospital, Department of Emergency and Internal Medicine, Malmö, Sweden (GRID:grid.411843.b) (ISNI:0000 0004 0623 9987)
14 Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Mexico (GRID:grid.419886.a) (ISNI:0000 0001 2203 4701)